Open-label, multicentre, randomised, trial of the safety and Efficacy of Doxycycline therapy versus National Standard therapy of Asymptomatic Covid-19

Period: 2020 - 2021


Faced with the threat of the SARS-Cov-2 epidemic, RSD Institute has made a commitment to the national health authorities for the management of COVID-19. As a result, a clinical trial was initiated by the Institute’s investigators to evaluate the efficacy of Doxycycline versus the combination of Hydroxychloroquine and Azithromycin (national guidelines) in treating asymptomatic or minimally symptomatic outpatients with COVID-19. Based on the positive results obtained in COVID-19 patients treated with Doxycycline, the investigators hypothesized that Doxycycline, an antimalarial antibiotic that can act on the virus and inflammation, could contribute to early disease control.

Patient recruitment and inclusion began in November 2020. The clinical trial is  implemented in the COVID-19 collection and
outpatient management center at Yaoundé Central Hospital.

The results of this study showed that Doxycycline was just as effective in the management of COVID-19 with fewer patient-reported side effects than the national protocol and thus constitutes an interesting alternative in the therapeutic arsenal against COVID-19